New combo aims to lower dangerous side effect in blood cancer patients

This early-phase study tests whether giving rituximab and high-dose steroids before venetoclax can safely shrink tumors in people with relapsed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to lower the risk of tumor lysis syndrome, a serious side effect from rapid cancer cell breakdown. About 4 adults who have already tried at least one prior treatment will participate.